

DAFTAR PUSTAKA

- Az'zahra, S. F., Nurhayati, E., Hartati, J., & Sawitri, N. (2024). Hubungan Antara Usia dan Jenis Kelamin dengan Kejadian Multidrug-Resistant Tuberculosis (MDR-TB) di Rumah Sakit Paru Dr. M. Goenawan (RSPG) Cisarua Bogor. *Bandung Conference Series: Medical Science*, 4(1), 899–905. <https://doi.org/10.29313/bcsms.v4i1.12431>
- Conradie, F., Bagdasaryan, T. R., Borisov, S., Howell, P., Mikiashvili, L., Ngubane, N., Samoilova, A., Skornykova, S., Tudor, E., Variava, E., Yablonskiy, P., Everitt, D., Wills, G. H., Sun, E., Olugbosi, M., Egizi, E., Li, M., Holsta, A., Timm, J., ... Spigelman, M. (2022). Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis. *New England Journal of Medicine*, 387(9), 810–823. <https://doi.org/10.1056/nejmoa2119430>
- Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E., Moreira, J., Timm, J., McHugh, T. D., Wills, G. H., Bateson, A., Hunt, R., Van Niekerk, C., Li, M., Olugbosi, M., & Spigelman, M. (2020). Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. *New England Journal of Medicine*, 382(10), 893–902. <https://doi.org/10.1056/nejmoa1901814>
- Dawis, A. M., Meylani, Y., Heryana, N., Alfathoni, M. A. M., Sriwahyuni, E., Ristiyana, R., Januarsi, Y., Wiratmo, P. A., Dasman, S., Mulyani, S., Agit, A., Shoffa, S., & Baali, Y. (2023). *Pengantar Metodologi Penelitian*.
- Dela, A. I., Tank, N. K. D., Singh, A. P., & Piparva, K. G. (2017). Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study. *Lung India*, 34(6), 522–526. <https://doi.org/10.4103/0970-2113.217569>
- Deshkar, A. T., & Shirure, P. A. (2022). Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis. *Cureus*, 14(8), 8–14. <https://doi.org/10.7759/cureus.28519>
- Franco, T. M. A., Favrot, L., Vergnolle, O., & Blanchard, J. S. (2017). Mechanism-Based Inhibition of the Mycobacterium tuberculosis Branched-Chain Aminotransferase by D- and L-Cycloserine. *ACS Chemical Biology*, 176(1), 1–24. <https://doi.org/10.1177/0022146515594631>.Marriage
- Gan, W. C., Ng, H. F., & Ngeow, Y. F. (2023). Mechanisms of Linezolid Resistance in Mycobacteria. *Pharmaceuticals*, 16(6), 1–11. <https://doi.org/10.3390/ph16060784>
- Guan, Y., & Liu, Y. (2020). Meta-analysis on Effectiveness and Safety of Moxifloxacin in Treatment of Multidrug Resistant Tuberculosis in Adults. *Medicine (United States)*, 99(25), E20648. <https://doi.org/10.1097/MD.00000000000020648>

- Harichander, S., Wiafe, E., Mensah, K. B., Bangalee, V., & Oosthuizen, F. (2022). The incidence of TB and MDR-TB in pediatrics and therapeutic options: a systematic review. *Systematic Reviews*, 11(1), 1–15. <https://doi.org/10.1186/s13643-022-02023-1>
- Hasanah, F., Dasopang, E. S., Bakri, T. K., & D, D. (2021). Evaluation of Potential Drug Side Effects in Multidrug-Resistant Tuberculosis Patients who have been Diagnosed by Genexpert Method. *Asian Journal of Pharmaceutical Research and Development*, 9(1), 8–11. <https://doi.org/10.22270/ajprd.v9i1.903>
- Hicks, N. D., Carey, A. F., Yang, J., Zhao, Y., & Fortunea, S. M. (2019). Bacterial genome-wide association identifies novel factors that contribute to ethionamide and prothionamide susceptibility in mycobacterium tuberculosis. *MBio*, 10(2). <https://doi.org/10.1128/mBio.00616-19>
- Jaber, A. A. S., & Ibrahim, B. (2019). Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: Data from centres with high drug resistance. *BMC Infectious Diseases*, 19(1), 1–9. <https://doi.org/10.1186/s12879-019-4069-1>
- Kemenkes RI. (2023). Pengobatan Tuberkulosis Resistan Obat dengan Panduan BPaL/M. In *Buku Pedoman Kementerian Kesehatan RI*.
- Kementrian Kesehatan RI. (2020). *Petunjuk Teknis Penatalaksanaan Tuberkulosis Resisten Obat di Indonesia*.
- Kura, M. M., Ramteke, M. N., & Dhillon, S. K. (2021). Second-line antitubercular therapy with ethionamide and pyrazinamide causing pellagroid dermatitis presenting as diffuse palmoplantar keratoderma. *JAAD Case Reports*, 17, 77–80. <https://doi.org/10.1016/j.jdc.2021.09.021>
- Koch, A., Cox, H., & Mizrahi, V. (2018). Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. *Current Opinion in Pharmacology*, 42, 7–15. <https://doi.org/10.1016/j.coph.2018.05.013>
- Maitre, T., Petitjean, G., Chauffour, A., Bernard, C., El Helali, N., Jarlier, V., Reibel, F., Chavanet, P., Aubry, A., & Veziris, N. (2017). Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis? *Journal of Antimicrobial Chemotherapy*, 72(8), 2326–2333. <https://doi.org/10.1093/jac/dkx150>
- Mudde, S. E., Upton, A. M., Lenaerts, A., Bax, H. I., & De Steenwinkel, J. E. M. (2022). Delamanid or pretomanid? A Solomonian judgement! *Journal of Antimicrobial Chemotherapy*, 77(4), 880–902. <https://doi.org/10.1093/jac/dkab505>
- Nilamsari, W. P., Rizqi, M. F., Regina, N. O., Wulaningrum, P. A., & Fatmawati, U. (2021). Adverse drug reaction and its management in tuberculosis patients with multidrug resistance: A retrospective study. *Journal of Basic and Clinical Physiology and Pharmacology*, 32(4), 783–787. <https://doi.org/10.1515/jbcpp-2020-0447>

- Nunn, A. J., Phillips, P. P. J., Meredith, S. K., Chiang, C.-Y., Conradie, F., Dalai, D., van Deun, A., Dat, P.-T., Lan, N., Master, I., Mebrahtu, T., Meressa, D., Moodliar, R., Ngubane, N., Sanders, K., Squire, S. B., Torrea, G., Tsogt, B., & Rusen, I. D. (2019). A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. *New England Journal of Medicine*, 380(13), 1201–1213. <https://doi.org/10.1056/nejmoa1811867>
- Nyang'wa, B.-T., Berry, C., Kazounis, E., Motta, I., Parpieva, N., Tigay, Z., Solodovnikova, V., Liverko, I., Moodliar, R., Dodd, M., Ngubane, N., Rassool, M., McHugh, T. D., Spigelman, M., Moore, D. A. J., Ritmeijer, K., du Cros, P., & Fielding, K. (2022). A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. *New England Journal of Medicine*, 387(25), 2331–2343. <https://doi.org/10.1056/nejmoa2117166>
- Nyang'wa, B. T., Berry, C., Kazounis, E., Motta, I., Parpieva, N., Tigay, Z., Moodliar, R., Dodd, M., Solodovnikova, V., Liverko, I., Rajaram, S., Rassool, M., McHugh, T., Spigelman, M., Moore, D. A., Ritmeijer, K., du Cros, P., Fielding, K., Da Costa, E., ... Mojaelo, E. (2024). Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. *The Lancet Respiratory Medicine*, 12(2), 117–128. [https://doi.org/10.1016/S2213-2600\(23\)00389-2](https://doi.org/10.1016/S2213-2600(23)00389-2)
- Reviono, Kusnanto, P., Eko, V., Pakiding, H., & Nurwidiasih, D. (2014). Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberkulosis. *Majalah Kedokteran Bandung*, 46(4), 189–196. <https://doi.org/10.15395/mkb.v46n4.336>
- Sahir, S. H. (2022). *Metodologi Penelitian* (M. S. Dr. Ir. Try Koryati (ed.)). KBM Indonesia.
- Sarathy, J., Blanc, L., Alvarez-Cabrera, N., O'Brien, P., Dias-Freedman, I., Mina, M., Zimmerman, M., Kaya, F., Liang, H.-P. H., Prideaux, B., Dietzold, J., Salgame, P., Savic, R. M., Linderman, J., Kirschner, D., Pienaar, E., & Dartois, V. (2019). Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. *Antimicrobial Agents and Chemotherapy*, 63(5), 1–16.
- Sari, G. A. P. L. P., & Herawati, F. (2023). Efektivitas dan keamanan terapi dengan rejimen yang mengandung linezolid dalam pengobatan multidrug-resistant tuberculosis (MDR-TB): Kajian Sistematis. *Pharmaceutical Journal of Indonesia*, 8(2), 179–186. <https://doi.org/10.21776/ub.pji.2023.008.02.10>
- Sharma, S. K., Mudgal, S. K., & Chaturvedi, J. (2020). Expression and interpretation of relative risk and odds ratio in biomedical research studies. *Indian Journal of Community Health*, 32(2), 344–347. <https://doi.org/10.47203/ijch.2020.v32i02.008>
- Stadler, J. A. M., Maartens, G., Meintjes, G., & Wasserman, S. (2023). Clofazimine for the treatment of tuberculosis. *Frontiers in Pharmacology*, 14(February),

1–18. <https://doi.org/10.3389/fphar.2023.1100488>

Sustrisna, M., & Rahmadani, E. (2022). Hubungan Usia dan Jenis Kelamin dengan TB MDR. *Sehat Rakyat: Jurnal Kesehatan Masyarakat*, 1(4), 370–376. <https://doi.org/10.54259/sehatrakyat.v1i4.1168>

Thomas, C., & Gwenin, C. D. (2021). The role of nitroreductases in resistance to nitroimidazoles. *Biology*, 10(5). <https://doi.org/10.3390/biology10050388>

Tiberi, S., Pontali, E., Tadolini, M., D'Ambrosio, L., & Migliori, G. B. (2019). Challenging MDR-TB clinical problems – The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. *International Journal of Infectious Diseases*, 80, S68–S72.

Van Deun, A., Monedero, I., Rieder, H. L., Heldal, E., Alarcon, E., Mace, C., Dlodlo, R. a, Fujiwara, P. I., Chiang, C.-Y., Harries, A. D., Trebucq, A., Armengol, R., Perrin, C., Cesari, G., & Enarson, D. a. (2013). *Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis 2013*.

WHO. (2022). WHO consolidated guidelines on tuberculosis. In *WHO Press*.

World Health Organization. (2021). Global Tuberculosis Report 2021: Supplementary Material. In *Global tuberculosis report 2021: supplementary material*. <https://www.who.int/publications/i/item/9789240037021>

World Health Organization. (2023). Global Tuberculosis Report. In *January* (Issue March)

Xu, J., Koval, A., & Katanaev, V. L. (2023). Clofazimine: A journey of a drug. *Biomedicine and Pharmacotherapy*, 167, 115539. <https://doi.org/10.1016/j.biopha.2023.115539>

Xu, X., Dong, B., Peng, L., Gao, C., He, Z., Wang, C., & Zeng, J. (2022). Anti-tuberculosis drug development via targeting the cell envelope of Mycobacterium tuberculosis. *Frontiers in Microbiology*, 13(December). <https://doi.org/10.3389/fmicb.2022.1056608>

